Monthly Archives

October 2021

Blackhawk Growth Files Fiscal Year Ended June 30, 2021 Financial Reports

Vancouver, British Columbia – TheNewswire – October 29, 2021 – Blackhawk Growth Corp. (CSNX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company”), is pleased to announce that the financial statements and MD&A for its fiscal year ended June 30, 2021 have been filed on Sedar. Highlights for the fiscal year ended June 30, 2021: – Blackhawk portfolio companies have recorded annual gross revenue of…

Read More

Blackhawk Growth’s Subsidiary MindBio Therapeutics Appoints Patrick Moher as Advisor

  Vancouver, British Columbia – TheNewswire – October 28, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Corporation” or “Blackhawk”), is pleased to announce that Microdose CEO, Patrick Moher, has been appointed to the MindBio advisory board and will provide strategic advice to the company in relation to industry and market trends and assist with content and publishing strategies….

Read More

Blackhawk Growth Appoints New Advisor to Support Expansion into Psychedelics And Mental Health Treatments

  Vancouver, British Columbia – TheNewswire – October 14, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that Dr. Lahiru Russell from Digital Mind Technology has been appointed as a medical advisor to Blackhawk. Dr. Russell, with over 10 years of experience in clinical trials and research in psycho-oncology, is developing a…

Read More

Blackhawk Growth’s SAC Pharma Continues to Expand Product Line and Services

Vancouver, British Columbia – TheNewswire – October 12, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company”), is excited to provide an update on the expansion of products and operations for Sac Pharma Partners USA (“SAC Pharma”), its wholly owned subsidiary. In an effort to further broaden its product line, Sac Pharma has secured four new exclusive cultivars on…

Read More

Blackhawk Growth’s MindBio Therapeutics Brings Digital Mental Health Technology To Psychedelics Clinical Trials

  Vancouver, British Columbia – TheNewswire – October 7, 2021 – Blackhawk Growth Corp. (CSE:BLR) (CNSX:BLR.CN) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that MindBio Therapeutics is developing a mental health technology platform to integrate with psychedelic treatments in clinical trials in patients suffering pain who are susceptible to depression, existential distress and anxiety. MindBio, a 100% owned…

Read More

Blackhawk Growth’s MindBio Therapeutics Successfully Progressed to the Second Half of their Phase 1 Microdosing Clinical Trial

Vancouver, British Columbia – TheNewswire – October  04, 2021 – Blackhawk Growth Corp. (CNSX:BLR.CN) (OTC:BLRZF) (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to announce that its subsidiary, MindBio Therapeutics, has successfully progressed to the second half of their fully funded Phase 1 clinical trial microdosing LSD to patients – this is the largest and first safety study of its kind…

Read More